Albertsons Companies (ACI) Earnings Date & Reports

Albertsons posted net sales and other revenue of $20.3 billion for Q4 fiscal 2025, up from $18.8 billion in the prior-year 12-week period, boosted by approximately $1.4 billion from the 53rd week. This slightly missed consensus of $20.49 billion.

GAAP net loss was $481 million or $(0.94) per share, driven by a $773.8 million pre-tax ($600 million net-of-tax) opioid settlement charge. Adjusted net income was $252 million or $0.48 per diluted share, surpassing estimates of $0.43-$0.44. Adjusted EBITDA rose to $903 million from $855 million, with $68 million from the extra week, reflecting productivity gains offsetting IRA pricing pressures and pharmacy mix shifts.

Identical sales increased 0.7%, led by pharmacy but hit by ~145 basis points of headwinds (105 bps IRA, 40 bps GLP-1 moderation). Digital sales grew 16%, loyalty members reached 51.2 million (up 12%). For full fiscal 2025, net sales were $83.2 billion (up from $80.4 billion), identical sales +2.0%, Adjusted EBITDA $3.9 billion (down slightly YoY due to pharmacy), and adjusted EPS $2.18.

Guidance for fiscal 2026 projects identical sales flat to +1.0% (1.5%-2.5% ex-IRA 150 bps headwind), Adjusted EBITDA $3.85-$3.925 billion, adjusted EPS $2.22-$2.32, capex $2.0-$2.2 billion, and tax rate 24%-25%.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your analysis.

Market Reaction and Investor Sentiment

ACI shares dropped 3.03% to $16.34 on April 14, 2026, after the pre-market release, as the revenue miss and large opioid charge overshadowed the EPS and EBITDA beats. Trading near its 52-week low of $15.80, sentiment focused on pharmacy headwinds exceeding expectations and conservative guidance amid grocery deflation. Analysts maintain a positive stance, with targets around $22 and ratings like Outperform from RBC, viewing the dip as a value entry given low P/E and raised shareholder returns.

Forward Outlook and Key Factors to Monitor

Albertsons enters fiscal 2026 with steady guidance, emphasizing productivity from a new $2 billion three-year program and investments in AI, digital, and supply chain. Identical sales face IRA headwinds, but ex-impact growth of 1.5%-2.5% signals underlying strength in grocery and pharmacy volumes.

Key metrics to watch include digital sales trajectory (21% FY growth) and loyalty program expansion, now at 51.2 million members. Pharmacy reimbursement and GLP-1 demand moderation remain risks, alongside fuel margins and private label performance in a low-deflation environment.

Capital allocation ramps up: a 13% dividend hike to $0.17/share (payable May 8, 2026), $2 billion buyback authorization, and $2.0-$2.2 billion capex for remodels (94 in FY2025), new stores (9), and tech. Debt refinancing supports a strong balance sheet.

Broader catalysts: industry M&A dynamics (post-Kroger bid scrutiny), consumer spending resilience, and execution on "Customers for Life" strategy. Investors should track Q1 results in July for early IRA impacts and productivity offsets.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations